NR1H4 and colorectal carcinoma: Li et al. found that FXR agonist obeticholic acid (OCA) inhibits the development and invasion of CRC by attenuating the EMT induced by Wnt/β-catenin and suppressing the activity of the Jak2/Stat3 pathway in human colon cancer cells [117].